A mostrar 1 - 20 resultados de 20 para a pesquisa 'D Yu Veltishchev', tempo de pesquisa: 0.05seg Refinar resultados
  1. 1
    Neurasthenia: history and the present

    Neurasthenia: history and the present Por D. Yu. Veltishchev

    Publicado em 2011-12-01
    Obter o texto integral
    Artigo
  2. 2
    Possibilities of using Tanakan ® in therapy for generalized anxiety syndrome

    Possibilities of using Tanakan ® in therapy for generalized anxiety syndrome Por D. Yu. Veltishchev

    Publicado em 2010-06-01
    Obter o texto integral
    Artigo
  3. 3
    MENTAL DISORDERS IN PATIENTS WITH RHEUMATIC DISEASES: DIAGNOSIS AND TREATMENT

    MENTAL DISORDERS IN PATIENTS WITH RHEUMATIC DISEASES: DIAGNOSIS AND TREATMENT Por T. A. Lisitsyna, D. Yu. Veltishchev

    Publicado em 2015-10-01
    Obter o texto integral
    Artigo
  4. 4
    Stressors and depressive disorders in rheumatic diseases

    Stressors and depressive disorders in rheumatic diseases Por Tatyana Andreyevna Lisitsyna, D Yu Veltishchev, E L Nasonov

    Publicado em 2013-04-01
    Obter o texto integral
    Artigo
  5. 5
    THE CLINICAL AND PATHOGENETIC RELATIONSHIP BETWEEN BEHCET'S DISEASE AND MENTAL DISORDERS

    THE CLINICAL AND PATHOGENETIC RELATIONSHIP BETWEEN BEHCET'S DISEASE AND MENTAL DISORDERS Por Daria Anatolyevna Ishchenko, D Yu Veltishchev, T A Lisitsyna, Z S Alekberova

    Publicado em 2013-12-01
    Obter o texto integral
    Artigo
  6. 6
    NARUShENIYa SNA U BOL'NYKh REVMATOIDNYM ARTRITOM I SISTEMNOY KRASNOY VOLChANKOY: EFFEKTIVNOST' I BEZOPASNOST' PREPARATA ZOLPIDEM (SANVAL)

    NARUShENIYa SNA U BOL'NYKh REVMATOIDNYM ARTRITOM I SISTEMNOY KRASNOY VOLChANKOY: EFFEKTIVNOST' I BEZOPASNOST' PREPARATA ZOLPIDEM (SANVAL) Por Tatyana Andreyevna Lisitsyna, O F Seravina, D Yu Vel'tishchev

    Publicado em 2010-10-01
    Obter o texto integral
    Artigo
  7. 7
    Anxiety, depression and stress tension screening in patients with rheumatic and musculoskeletal diseases at the onset of the 2019 coronavirus disease (COVID-19) pandemic

    Anxiety, depression and stress tension screening in patients with rheumatic and musculoskeletal diseases at the onset of the 2019 coronavirus disease (COVID-19) pandemic Por A. B. Borisova, T. A. Lisitsyna, D. Yu. Veltishchev, E. L. Nasonov

    Publicado em 2021-12-01
    Obter o texto integral
    Artigo
  8. 8
    STRESS FACTORS AND MENTAL DISORDERS IN SJOGREN'S DISEASE: MODERN TRENDS IN RESEARCH

    STRESS FACTORS AND MENTAL DISORDERS IN SJOGREN'S DISEASE: MODERN TRENDS IN RESEARCH Por Olga Aleksandrovna Shelomkova, D Yu Veltishchev, V I Vasilyev, T A Lisitsyna

    Publicado em 2012-10-01
    Obter o texto integral
    Artigo
  9. 9
    Interleukin 6 as a pathogenic factor mediating clinical manifestations and a therapeutic target for rheumatic diseases and depressive disorders

    Interleukin 6 as a pathogenic factor mediating clinical manifestations and a therapeutic target for rheumatic diseases and depressive disorders Por T. A. Lisitsyna, D. Yu. Veltishchev, A. M. Lila, E. L. Nasonov

    Publicado em 2019-07-01
    Obter o texto integral
    Artigo
  10. 10
    Psychiatric aspects of spondyloarthritis

    Psychiatric aspects of spondyloarthritis Por T. A. Lisitsyna, D. Yu. Veltishchev, E. L. Nasonov, A. M. Lila

    Publicado em 2021-01-01
    Obter o texto integral
    Artigo
  11. 11
    Anxiety-depressive spectrum disorders in patients with obstetric antiphospholipid syndrome

    Anxiety-depressive spectrum disorders in patients with obstetric antiphospholipid syndrome Por A. B. Borisova, D. Yu. Veltishchev, T. M. Reshetnyak, T. A. Lisitsyna, E. L. Nasonov

    Publicado em 2024-12-01
    Obter o texto integral
    Artigo
  12. 12
    THE IMPACT OF ADEQUATE PSYCHOPHARMACOTHERAPY ON THE EFFICIENCY OF TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS

    THE IMPACT OF ADEQUATE PSYCHOPHARMACOTHERAPY ON THE EFFICIENCY OF TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS Por A. A. Abramkin, T. A. Lisitsyna, D. Yu. Veltishchev, O. F. Seravina, O. B. Kovalevskaya, E. L. Nasonov

    Publicado em 2018-05-01
    Obter o texto integral
    Artigo
  13. 13
    EFFECTS OF SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS, BIOLOGICAL AGENTS, AND PSYCHOPHARMACOTHERAPY ON THE MENTAL DISORDERS IN PATIENTS WITH RHEUMATOID ARTHRITIS

    EFFECTS OF SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS, BIOLOGICAL AGENTS, AND PSYCHOPHARMACOTHERAPY ON THE MENTAL DISORDERS IN PATIENTS WITH RHEUMATOID ARTHRITIS Por A. A. Abramkin, T. A. Lisitsyna, D. Yu. Veltishchev, O. F. Seravina, O. B. Kovalevskaya, E. L. Nasonov

    Publicado em 2017-09-01
    Obter o texto integral
    Artigo
  14. 14
    FACTORS INFLUENCING THE EFFICIENCY OF THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS: THE ROLE OF COMORBID MENTAL AND SOMATIC DISEASES

    FACTORS INFLUENCING THE EFFICIENCY OF THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS: THE ROLE OF COMORBID MENTAL AND SOMATIC DISEASES Por A. A. Abramkin, T. A. Lisitsyna, D. Yu. Veltishchev, O. F. Seravina, O. B. Kovalevskaya, S. I. Glukhova, E. L. Nasonov

    Publicado em 2018-09-01
    Obter o texto integral
    Artigo
  15. 15
    Cognitive impairments in patients with rheumatoid arthritis and comorbid anxiety and depressive disorders: Outcomes of the five-years prospective study

    Cognitive impairments in patients with rheumatoid arthritis and comorbid anxiety and depressive disorders: Outcomes of the five-years prospective study Por A. A. Abramkin, T. A. Lisitsyna, D. Yu. Veltishchev, O. F. Seravina, O. B. Kovalevskaya, S. I. Glukhova, E. L. Nasonov

    Publicado em 2024-11-01
    Obter o texto integral
    Artigo
  16. 16
    FACTORS ASSOCIATED WITH ANXIETY AND DEPRESSION SPECTRUM DISORDERS IN BEHCHET’S DISEASE

    FACTORS ASSOCIATED WITH ANXIETY AND DEPRESSION SPECTRUM DISORDERS IN BEHCHET’S DISEASE Por P. S. Ovcharov, T. A. Lisitsyna, D. Yu. Veltishchev, O. F. Seravina, O. B. Kovalevskaya, S. I. Glukhova, Z. S. Alekberova, E. L. Nasonov

    Publicado em 2018-07-01
    Obter o texto integral
    Artigo
  17. 17
    Objective: to specify the frequency and pattern of mental disorders in patients with rheumatoid arthritis (RA) and their association with a number of demographic parameters, stressors, inflammatory activity, duration of RA and its therapy, pain, and concomitant cardiovascular diseases (CVD).Subject and methods. One hundred and sixteen patients with verified RA were examined; 86% were women with a median age of 50 years (range, 41 to 55 years) and a median RA duration of 94.5 months (range, 45 to 228 months). Disease activity was assessed using the DAS 28 scoring system; the Brief Pain Inventory (BPI) was used for pain assessment. CVD was diagnosed by a cardiologist applying echocardiography, Doppler ultrasound, and 24-hour and blood pressure monitoring. Mental disorders were identified by a psychiatrist in accordance with ICD-10, by employing a number of psychiatric and psychological scales.Results. Mental disorders were found in 86% of the patients. There was a preponderance (85%) of anxiety-depressive spectrum disorders (ADSD): depressive episode (37%), including that within recurrent depressive disorder (19%); dysthymia (23%); adjustment disorders (16%); and generalized anxiety disorder (9%). Moderate cognitive impairment was revealed in 52% of the patients with ADSD. Schizophrenia was detected in 1%; 76 % of the RA patients had sleep disorders; 63 and 52% reported a stressful event at the onset of RA or before its exacerbation, respectively. The patients with ADSD did not differ from those without ADSD in age, gender, disease duration and activity, but they had more frequently aseptic bone necroses (ABN), X-ray stage IV, Class III functional insufficiency (FI), higher severity index and HAQ index. The patients with ADSD experienced stronger pain (p < 0.05). They took glucocorticoids for a shorter time (p < 0.05). Basic anti-inflammatory drugs were taken by the patients with and without ADSD at a similar frequency, but the patients with ADSD received methotrexate less often. ADSD was more common in patients with RA and CVD (angina pectoris, atherosclerosis, acute cerebrovascular insufficiency). Conclusion. Mental disorders with a predominance of ADSD are typical of the majority of patients with RA. Stressful events often precede the onset of RA and its exacerbation. The incidence of ADSD does not depend on age, gender, and disease duration and activity, but correlates with joint destructive changes (ABN and X-ray stage IV), pain intensity, FI, severity index and HAQ, less aggressive therapy for RA, and CVD.

    Objective: to specify the frequency and pattern of mental disorders in patients with rheumatoid arthritis (RA) and their association with a number of demographic parameters, stress... Por T A Lisitsyn, D Yu Veltishchev, O F Seravina, O B Kovalevskaya, A E Zeltyn, Yu S Fofanova, D S Novikova, T V Popkova, E L Nasonov

    Publicado em 2011-06-01
    Obter o texto integral
    Artigo
  18. 18
    Efficacy of olokizumab against comorbid depressive disorder in patients with rheumatoid arthritis: Preliminary results of the study

    Efficacy of olokizumab against comorbid depressive disorder in patients with rheumatoid arthritis: Preliminary results of the study Por T. A. Lisitsyna, A. A. Abramkin, D. Yu. Veltishchev, O. F. Seravina, O. B. Kovalevskaya, A. B. Borisova, V. G. Ignatiev, E. L. Nasonov

    Publicado em 2023-04-01
    Obter o texto integral
    Artigo
  19. 19
    Proinflammatory cytokines and depression in rheumatoid arthritis

    Proinflammatory cytokines and depression in rheumatoid arthritis Por Tatyana Andreyevna Lisitsyna, D Yu Veltishchev, O F Seravina, O B Kovalevskaya, A E Zeltyn, A A Novikov, E N Aleksandrova, V N Krasnov, E L Nasonov

    Publicado em 2013-06-01
    Obter o texto integral
    Artigo
  20. 20
    Mental disorders in antiphospholipid syndrome patients: association with clinical and immunological manifestations of the disease

    Mental disorders in antiphospholipid syndrome patients: association with clinical and immunological manifestations of the disease Por А. В. Borisova, Т. А. Lisitsyna, D. Yu. Veltishchev, Т. М. Reshetnyak, О. F. Seravina, О. В. Kovalevskaya, F. А. Cheldieva, А. А. Abramkin, А. Е. Zeltyn, Е. L. Nasonov

    Publicado em 2024-04-01
    Obter o texto integral
    Artigo

Ferramentas de pesquisa: